Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of TK-023 (high-dose donepezil) in severe Alzheimer's-type dementia
jRCT2080224612Phase 3Completed
- Sponsor
- Teikoku Seiyaku Co., Ltd.
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of donepezil in Alzheimer's disease (AD), sponsored by Teikoku Seiyaku Co., Ltd. Started Mar 2019; status: completed.
02
Drugs
donepezil
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2080224612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224612.